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Th1 cytokines promote monocyte differentia-
tion into proatherogenic M1 macrophages,
while Th2 cytokines lead to an ‘‘alternative’’
anti-inflammatory M2 macrophage phenotype.
Here we show that in human atherosclerotic
lesions, the expression of M2 markers and
PPARg, a nuclear receptor controlling macro-
phage inflammation, correlate positively. More-
over, PPARg activation primes primary human
monocytes into M2 differentiation, resulting in
a more pronounced anti-inflammatory activity
in M1 macrophages. However, PPARg activa-
tion does not influence M2 marker expression
in resting or M1 macrophages, nor does PPARg
agonist treatment influence the expression of
M2 markers in atherosclerotic lesions, indicat-
ing that only native monocytes can be primed
by PPARg activation to an enhanced M2 pheno-
type. Furthermore, PPARg activation signifi-
cantly increases expression of the M2 marker
MR in circulating peripheral blood mononuclear
cells. These data demonstrate that PPARg
activation skews human monocytes toward an
anti-inflammatory M2 phenotype.
INTRODUCTION
A crucial step in atherogenesis consists of the infiltration of
the subendothelial space of large arteries by monocytes,
where they differentiate into macrophages (Ross, 1999).
Macrophages are a heterogeneous cell population that
adapt and respond to a large variety of microenvironmen-
tal signals (Van Ginderachter et al., 2006). The activation
state and functions of mononuclear phagocytes areCellprofoundly affected by different cytokines and microbial
products. While Th1 cytokines, such as interferon g
(IFNg), interleukin-1b (IL-1b), and lipopolysaccharide
(LPS), induce a ‘‘classical’’ activation profile (M1), Th2
cytokines, such as IL-4 and IL-13, induce an ‘‘alternative’’
activation program (M2) in macrophages. Moreover, mac-
rophages are plastic cells because they can switch from
an activated M1 state back to M2, and vice versa, upon
specific signals (Porcheray et al., 2005). M1 macrophages
are potent effector cells that kill microorganisms and pro-
duce primarily proinflammatory cytokines, such as tumor
necrosis factor a (TNF-a), IL-6, and IL-12 (Gordon,
2003). In contrast, M2 macrophages dampen these
inflammatory and adaptive Th1 responses by producing
anti-inflammatory factors (IL-10, transforming growth
factor b [TGF-b], and IL-1 receptor antagonist [IL-1Ra]),
scavenging debris, and promoting angiogenesis, tissue
remodeling, and repair (Gordon, 2003; Mantovani et al.,
2001). Thus, inflammatory diseases, such as atheroscle-
rosis, may be caused not only by a sustained proinflam-
matory reaction but also by failure of anti-inflammatory
control mechanisms.
Peroxisome proliferator-activated receptor g (PPARg) is
a ligand-activated nuclear receptor with potent anti-
inflammatory properties that modulates the immune
inflammatory response (Chinetti et al., 2003). Transcrip-
tional repression of inflammatory response genes occurs
by negative interference of PPARg with the nuclear factor
kB (NF-kB), signal transducer and activator of transcrip-
tion (STAT), and activating protein 1 (AP-1) signaling
pathways (Chinetti et al., 2000a). In activated M1 macro-
phages, the PPARg-dependent transrepression pathway
is initiated by sumoylation of the liganded PPARg ligand-
binding domain maintaining the corepressor complex on
NF-kB response elements (Pascual et al., 2005). PPARg
is activated by natural (15-deoxy-D12;14-prostaglandin
J2 [15d-PGJ2]) (Kliewer et al., 1995) and synthetic ligands,
including the antidiabetic thiazolidinediones (TZDs) (suchMetabolism 6, 137–143, August 2007 ª2007 Elsevier Inc. 137
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PPARg and M2 Differentiation of Human MacrophagesFigure 1. M1 and M2 Macrophage Markers Are Expressed in Human Carotid Atherosclerotic Lesions
RNA was extracted from human carotid atherosclerotic lesions and adjacent zones. mRNA levels were measured by qPCR and are represented in box
plots indicating the median and the lower and upper quartiles. Statistically significant differences are indicated (paired Student’s t test; p < 0.05).as rosiglitazone and pioglitazone) and the GW1929 com-
pound (Willson et al., 2000). PPARg is abundantly ex-
pressed in macrophages, where its expression is rapidly
induced upon differentiation of monocytes into macro-
phages (Chinetti et al., 1998). In atherosclerotic lesion
macrophages, PPARg modulates cholesterol homeo-
stasis and the inflammatory response (Chinetti et al.,
2000b, 2003). Moreover various leukocyte populations,
including lymphocytes and dendritic cells, also express
PPARg, suggesting a role for this receptor in the regulation
of the immune response (Standiford et al., 2005).
In the present study, we evaluated whether PPARg, in
addition to its well-described anti-inflammatory action in
M1 macrophages, could also exert anti-inflammatory
activities by modulating the M1/M2 differentiation of
monocytes into macrophages.
RESULTS
M2 Macrophage Markers Are Present in Human
Carotid Atherosclerotic Lesions and Correlate
Positively with PPARg Expression Levels
Previous studies have identified the presence and role of
activated M1 macrophages in atherosclerosis (Ross,
1999). However, it was unknown whether M2 macro-
phages are present in atherosclerotic lesions. Therefore,
we performed M1 and M2 marker RNA analysis on carotid138 Cell Metabolism 6, 137–143, August 2007 ª2007 Elsevier Inplaques isolated by endarterectomy from 27 patients.
Interestingly, atherosclerotic lesions, which are enriched
in macrophages as demonstrated by the high expression
level of CD36 when compared to the adjacent zone
(Figure 1), contain both macrophage subpopulations.
Both markers of the M1 state, such as MCP-1, IL-6, and
TNF-a, as well as markers of M2 activation, such as
CD163, MR (mannose receptor; also called CD206),
AMAC1 (alternative macrophage activation-associated
CC chemokine 1; also called chemokine [C-C motif] ligand
18 [CCL-18]), and IL-10, are more abundantly expressed
in the pathological tissue compared to the adjacent zone
(Figure 1).
Moreover, the staining pattern of MR in serial sections of
human atherosclerotic plaques showed that this M2
marker is expressed in the same infiltration area of
CD68-positive macrophages (Figure 2A). Interestingly,
the macrophage population expressing MR displays a dis-
tinct tissue distribution profile compared to foam cells
(lipid-laden macrophages). Furthermore, staining with
anti-MCP-1 antibody, an M1 marker, indicated that MR-
positive cells and MCP-1-positive cells present a distinct
tissue localization pattern (Figure 2A). These results
show the presence of at least two macrophage popula-
tions in human atherosclerotic plaques.
As previously shown (Chinetti et al., 2000b, 2003),
PPARg is also abundantly expressed in lesionc.
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PPARg and M2 Differentiation of Human MacrophagesFigure 2. MR Protein Is Present in Human Carotid Atherosclerotic Lesions Where M2 Macrophage Markers Correlate Positively
with PPARg Expression Levels
(A) Representative staining pattern for Oil red O, CD68, MR, and MCP-1 in adjacent cryosections of a human complicated carotid atherosclerotic
lesion with lipid-rich cores. Infiltrated MR- (arrows) or MCP-1-positive cells within a macrophage-rich area surrounded by CD68-positive foam cells
(arrowheads) are indicated. Scale bar = 100 mm.
(B) Pearson correlation coefficients (r) and multiple regression analysis were calculated from qPCR DCt data. Confidence intervals of 90% are indi-
cated by the dashed arcs. Statistically significant differences are indicated (t test; p < 0.05).macrophages of atherosclerotic plaques (Figure 1). More-
over, its expression correlates with the expression of
CD36, a scavenger receptor marker of macrophages
and known PPARg target gene (data not shown; Tontonoz
et al., 1998). In addition, PPARg expression levels corre-
late positively with the expression of M2 markers, such
asMR,AMAC1, and IL-10 (Figure 2B). By contrast, no cor-
relation was observed between PPARg and the M1
markers TNF-a, MCP-1, and IL-6 (Figure 2B). Taken
together, these results suggest a potential functional
relationship between PPARg and the M2 macrophage
subpopulation.
PPARg Agonists Enhance the Alternative
Differentiation of Human Monocytes into
Macrophages In Vitro
To determine whether PPARg plays a role in M2 differenti-
ation, primary human monocytes were differentiated
in vitro into alternative macrophages with recombinant
IL-4 in the absence (M2) or in the presence (M2g) of the
PPARg agonists GW1929 (600 nM) or rosiglitazone
(100 nM) added only at the beginning of the differentiation
process. As expected (Stein et al., 1992), the M2 macro-Cell Mphage marker MR was strongly induced by IL-4
(Figure 3A). Interestingly, this effect was amplified by
both PPARg agonists (Figure 3A). By contrast, the expres-
sion ofCD163was significantly reduced after IL-4 stimula-
tion (Figure 3A), in line with previous reports (Porcheray
et al., 2005; Van den Heuvel et al., 1999). The presence
of both PPARg agonists enhanced the IL-4-induced
decrease of CD163 expression in M2g macrophages
(Figure 3A). A similar regulation of MR and CD163 expres-
sion by the PPARg ligands was observed in monocytes dif-
ferentiated into M2 macrophages in the presence of IL-13
or an IL-4/IL-13 combination (see Figure S1 in the Supple-
mental Data available with this article online). As previously
reported in resting macrophages (RM), PPARg expression
was also induced by IL-4 (Huang et al., 1999) and/or IL-13
in M2 differentiating macrophages (data not shown).
Flow cytometry analysis of RM, M2, and M2g macro-
phages demonstrated, as expected, higher MR protein
levels in M2 compared to RM. Moreover, MR expression
was further enhanced in M2g (Figure 3B). On the other
hand, CD163 expression was lower in M2 compared to
RM, and its expression was further reduced in M2g (data
not shown). By contrast, MR and CD163 protein levelsetabolism 6, 137–143, August 2007 ª2007 Elsevier Inc. 139
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PPARg and M2 Differentiation of Human MacrophagesFigure 3. PPARg Activation Promotes the Acquisition of an M2 Phenotype in Primary Human Monocytes and Enhances the Anti-
inflammatory Properties of M2 Macrophages
(A) MR and CD163 mRNA was measured in RM and M2 macrophages treated with GW1929 (gray columns, 600 nM), rosiglitazone (black columns,
100 nM), or vehicle (white columns). Each bar is the mean value ± SD of triplicate determinations, representative of five independent experiments.
Statistically significant differences are indicated (t test; §§§p < 0.001 for RM versus M2, **p < 0.01 and *p < 0.05 for vehicle versus GW1929 or ro-
siglitazone in M2).
(B) MR protein expression was analyzed by flow cytometry in RM, M2, and M2g cells. Values represent the percentage of positive cells. The percent-
age of autofluorescence is 0.39%.
(C) Primary human monocytes were differentiated to M2 in the presence or absence of GW1929 (600 nM) and/or GW9662 (1 mM) added only at the
beginning of the differentiation process. MR and CD163 mRNA levels were analyzed; each bar is the mean value ± SD of triplicate determinations,
representative of three independent experiments. Statistically significant differences are indicated (t test; **p < 0.01 and *p < 0.05).
(D) MCP-1, TNF-a, and CCL-3 were quantified in macrophage supernatants (see Supplemental Data). Each bar is the mean value ± SD of triplicate
determinations, representative of two independent experiments. Statistically significant differences are indicated (t test; ***p < 0.001, **p < 0.01, and
*p < 0.05).were not affected by PPARg activation upon addition of
the agonists to monocytes differentiating into RM (data
not shown), indicating that PPARg activation only modu-
lates M2 markers in monocytes polarized to M2 with IL-4
and/or IL-13.
Finally, coincubation of monocytes undergoing M2g
differentiation with the PPARg antagonist GW9662 com-
pletely abolished the regulation ofMR andCD163 expres-
sion by the PPARg agonists, indicating that the observed
effects are PPARg dependent (Figure 3C).
M2 Macrophages Exert Paracrine Anti-inflammatory
Effects on M1 Macrophages
To examine whether PPARg-agonist-primed M2 macro-
phages can influence the inflammatory status of activated
M1 macrophages, indirect coculture experiments were
performed. Differentiated RM were incubated for 24 hr140 Cell Metabolism 6, 137–143, August 2007 ª2007 Elsevier Inin medium supplemented with M2 or M2g culture superna-
tant and subsequently stimulated with LPS to induce an
M1 phenotype. Cytokines and chemokines released by
M1 macrophages were then quantified by enzyme-linked
immunosorbent assay (ELISA) (Figure S2). As expected,
incubation of M1 macrophages with M2-derived culture
supernatant resulted in a pronounced inhibition of the se-
cretion of proinflammatory molecules, such as CCL-3,
TNF-a, and MCP-1 (Figure 3D). Interestingly, this inhibitory
effect was significantly enhanced when M1 macrophages
were incubated with medium from M2 primed in the pres-
ence of the PPARg agonist GW1929 (Figure 3D). These
results confirm that M2 macrophages dampen the inflam-
matory status of surrounding M1 macrophages and that
priming toward M2 differentiation by PPARg activation
enhances the anti-inflammatory properties of M2 macro-
phages.c.
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PPARg and M2 Differentiation of Human MacrophagesFigure 4. PPARg Activation Induces M2 Markers in Human Blood Mononuclear Cells In Vivo
(A) RNA was extracted from human carotid atherosclerotic lesions isolated from 7 placebo- and 8 rosiglitazone (TZD)-treated subjects. Each point
represents mRNA expression analysis of a single patient, and the bar indicates the mean. Statistically significant differences are indicated (Mann-
Whitney rank-sum test; *p < 0.05).
(B) RNA was extracted from peripheral blood mononuclear cells isolated from 15 patients before and after 2 months of 45 mg/day pioglitazone (TZD)
treatment. mRNA levels are represented in box plots in which the median is surrounded by the lower and upper quartile. Statistically significant dif-
ferences are indicated (t test; ***p < 0.001).PPARg Activation Does Not Switch RM, M1, or Foam
Cells into an M2 Phenotype In Vitro
Previous studies have demonstrated that macrophages
are plastic cells because they can switch from an acti-
vated M1 state back to M2, and vice versa, upon specific
signals (Porcheray et al., 2005). Hence, we tested whether
the incubation of RM at the end of differentiation with IL-4
and/or PPARg ligands could revert the M1 phenotype to
M2. In the absence of IL-4, PPARg activation did not influ-
ence the expression of the M2 markers MR, AMAC1, and
CD163 in RM (Figure S3A). Treatment of fully differentiated
RM with IL-4 induced a switch to an M2 phenotype, but
this effect was not further enhanced by PPARg activation,
except for AMAC1, which was slightly (albeit not signifi-
cantly) repressed in the presence of PPARg ligands
(Figure S3B). To mimic the resident macrophages in ath-
erosclerotic lesions, which appear predominantly as M1
macrophages or foam cells, experiments were performed
on RM incubated with different proinflammatory stimuli
(IL-1b, TNF-a, or LPS) to induce an M1 status or with
AcLDL to induce lipid accumulation, in the absence or in
the presence of the PPARg agonists GW1929 (600 nM)
or rosiglitazone (100 nM). However, PPARg activation
was not able to redirect M1 or foam-cell macrophages to-
ward an M2 phenotype, as indicated by the absence of M2
marker regulation (Figures S3C and S3D). Taken together,
these data suggest that PPARg activation promotes M2
phenotype enhancement only in monocytes, and not in
differentiated RM or M1 macrophages.CellPPARg Activation Directs Human Blood Precursor
Cells toward an M2 Phenotype In Vivo
To determine whether these in vitro observations also
occur in vivo in humans, macrophage markers were
measured in RNA isolated from atherosclerotic lesions
from placebo- or rosiglitazone (TZD)-treated individuals.
Interestingly, rosiglitazone treatment did not modify the
expression of the M2 markers MR and CD163. By con-
trast, the expression of CD36, a known PPARg target
gene in macrophages (Tontonoz et al., 1998), was sig-
nificantly increased in plaques of TZD-treated patients
(Figure 4A). These results are in line with those
obtained in vitro in M1 and foam cells, indicating that
PPARg is unable to influence the expression of M2
markers in established atherosclerotic lesion macro-
phages.
Since PPARg agonists enhance monocyte differentia-
tion toward an M2 phenotype in vitro, it was investigated
whether this regulation also occurs in vivo. Peripheral
blood mononuclear cells (PBMC), a cell population includ-
ing circulating monocytes, were isolated from patients
before and after pioglitazone administration (Balmforth
et al., 2007). Interestingly, TZD treatment significantly
increased the expression of the M2 marker MR in PBMC
(Figure 4B). Surprisingly, the expression of PPARg in
PBMC was also increased by TZD treatment. Taken
together, these results suggest that PPARg activation
could also be able to program precursor mononuclear
cells toward an M2 phenotype in vivo.Metabolism 6, 137–143, August 2007 ª2007 Elsevier Inc. 141
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Monocytes are precursors of macrophages, which are
prominent cells in the host response to lipid accumulation
in large arteries that contribute to the development of
atherosclerosis and its complications. Very recently,
a monocyte subpopulation characterized by high levels
of the LY-6C marker antigen has been shown to dominate
hypercholesterolemia-associated monocytosis in mice
and to give rise to the macrophages in atherosclerotic
lesions (Swirski et al., 2007; Tacke et al., 2007). LY-6Chi
monocytes, which correspond to human CD14hiCD16
monocytes, preferentially migrate to lesions with high
inflammatory activity and populate sites of experimentally
induced inflammation (Swirski et al., 2007; Tacke et al.,
2007). This observation indicates that cell heterogeneity
of circulating monocytes influences plaque formation
and phenotype. Moreover, mature tissue macrophages
also exhibit a level of heterogeneity reflecting the plasticity
and versatility of these cells in response to microenviron-
mental signals (Gordon, 2007). Microbial stimuli, such as
LPS as well as Th1 cytokines, activate macrophages
into an M1 inflammatory state, while Th2 cytokines, such
as IL-4, polarize cells to an M2 phenotype with immuno-
regulatory, repairing, and anti-inflammatory functions
(Gordon, 2003). However, whether the cytokine tissue
environment recruits and/or activates specific monocyte
subsets or rather polarizes already accumulated subsets
of particular macrophages is not known at the moment.
Until now, the presence of M2 macrophages in human
atherosclerotic lesions had not been demonstrated.
Here we provide evidence for macrophage heterogeneity
in atherosclerosis, since both M1 and M2 macrophage
markers are detectable in human atherosclerotic lesions.
Immunohistological analysis shows that M2 macrophages
positively stained for CD68 and MR are present at loca-
tions distant from the lipid core in more stable zones of
the plaque. Interestingly, in human atherosclerotic pla-
ques, expression of PPARg, a transcription factor with
anti-inflammatory properties in macrophages, correlates
positively with the expression of M2 markers. These
observations prompted us to investigate whether PPARg
plays a role in the differentiation program of monocytes
into the M2 phenotype in vitro. Our results show that
PPARg activation primes monocytes into an enhanced
M2 phenotype. Moreover, these PPARg-primed M2
macrophages exert more pronounced anti-inflammatory
properties on M1 macrophages. One well-established
pathway via which PPARg controls the inflammatory re-
sponse is by negatively interfering with proinflammatory
signaling pathways such as AP-1, NF-kB, or STAT-3 in
activated M1 macrophages (Chinetti et al., 2003). More re-
cently, it has been shown that the PPARg-dependent
transrepression pathway is initiated by sumoylation of
the liganded PPARg ligand-binding domain maintaining
the corepressor complex on NF-kB response elements,
thus preventing inflammatory response genes from being
activated (Pascual et al., 2005). Our observations provide
evidence for an additional mechanism by which PPARg142 Cell Metabolism 6, 137–143, August 2007 ª2007 Elseviercan exert anti-inflammatory activities in macrophages.
This mechanism is mainly operative in native monocytes
that, in the presence of an appropriate M2 stimulus such
as IL-4, can be primed by PPARg ligands to an enhanced
M2 phenotype. By contrast, PPARg activation does not
influence the expression of M2 markers in already differ-
entiated RM and M1 programmed macrophages or foam
cells, an effect that is associated in vivo with the absence
of M2 marker regulation by rosiglitazone in established
atherosclerotic lesions isolated from treated patients.
However, TZD administration reduces lesion inflammation
and increases collagen content and plaque stability in the
same subjects (Meisner et al., 2006). These observations
indicate that, in established atherosclerotic lesion macro-
phages, the anti-inflammatory actions of TZD are due to
a reduction of M1 macrophage activation state, mirrored,
for example, by decreasing the expression of matrix-
degrading metalloproteinases (Meisner et al., 2006). Inter-
estingly, TZD treatment significantly increased expression
ofMR in PBMC, a heterogeneous cell population including
circulating monocytes, thus suggesting that PPARg acti-
vation can program mononuclear precursor cells toward
an M2 phenotype in vivo. This would lead to generation
of a macrophage population with enhanced anti-
inflammatory properties. Our data highlight the action of
PPARg ligands and suggest that TZD may be particularly
efficient in the prevention of cardiovascular complications
of type 2 diabetes.
EXPERIMENTAL PROCEDURES
Endarterectomy Tissue Samples
Human atherosclerotic plaques were removed from 27 patients eligible
for surgical carotid endarterectomy (Zawadzki et al., 2006). Carotid
plaques were obtained from 15 nondiabetic patients with symptomatic
carotid artery stenosis randomized to 4 weeks placebo or rosiglitazone
before surgery (Meisner et al., 2006).
Immunohistochemical Analysis
Serial cryosections from endarterectomy specimens were stained with
Oil red O, anti-human CD68 (DakoCytomation), anti-human MR, or
anti-human MCP-1 (Santa Cruz Biotechnology).
Cell Culture
Primary human monocyte differentiation in resting macrophages (RM)
occurred after 7 days of culture. Alternatively differentiated macro-
phages (M2) were obtained by stimulating monocytes with human
IL-4, IL-13 (15 ng/ml), or a combination of both (10 ng/ml each). The
PPARg agonists GW1929 (600 nM) or rosiglitazone (100 nM) or the
PPARg antagonist GW9662 (1 mM) was added during differentiation.
RM were activated to M1 macrophages by IL-1b (5 ng/ml), TNF-a
(5 ng/ml), or LPS (100 ng/ml) or were transformed to foam cells by
acetylated LDL.
Indirect M1/M2 Coculture Experiments
M2 or M2g (M2 differentiated in the presence of PPARg ligands) culture
medium was added to RM 24 hr before LPS (100 ng/ml) stimulation.
After 4 hr, M1 macrophages were washed and cultured for 24 hr in
fresh medium. The resulting media were assayed for cytokine and
chemokine secretion by ELISA (PeproTech).Inc.
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Total RNA isolated from human carotid plaques, macrophages, and
PBMC isolated from subjects enrolled in the pioglitazone and ultra-
sound evaluation study before and after 2 months of pioglitazone
administration (Balmforth et al., 2007) was reverse transcribed. cDNAs
were quantified by qPCR using specific primers.
Flow Cytometry Analysis
Protein analysis was performed using a FACStar Plus with PE-Cy5-
conjugated anti-MR or PE-conjugated anti-CD163 human antibodies
(BD Biosciences PharMingen).
Statistical Analysis
Pearson correlation coefficients (r) and multiple regression analysis
were calculated from qPCR DCt data using R statistical software
(http://www.r-project.org/). Statistical differences between groups
were analyzed by Student’s t test and Mann Whitney rank-sum test
and were considered significant at p < 0.05.
For more details, see Supplemental Experimental Procedures.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, one table, and three figures and can be
found with this article online at http://www.cellmetabolism.org/cgi/
content/full/6/2/137/DC1/.
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